Subscribe to get full access to this operation and the extensive Hip Surgery Atlas.

FREE TRIAL

---

Learn the Congenital dislocation of the Hip: Medial Approach Open Reduction hip (MAOR) surgical technique with step by step instructions on OrthOracle. Our e-learning platform contains high resolution images and a certified CME of the Congenital dislocation of the Hip: Medial Approach Open Reduction hip (MAOR) surgical procedure.

 

Medial approach open reduction (MAOR) was first described by Ludloff in 1908. Several variations have been described. This technique is a modification of the original with tenodesis of the ligament teres as described by Torode (JPO 2008). This operation is typically utilised for patients presenting between 6 and 18 months of age.

The indication for MAOR is the dislocated hip that is either irreducible or unstable on attempted closed reduction. The procedure has been utilised from the age of 3 months up to 2 years but typically is used from 6 to 18 months.

Anterior open reduction(AOR) is widely practiced as an alternative to MAOR. AOR has the advantage that reefing of the capsule can be performed to increase stability. In addition AOR can be combined with pelvic osteotomy. Therefore this is the preferred approach for children presenting after 18 months where residual acetabular dysplasia is unlikely to resolve.

MAOR has the advantage that it can be performed through a small incision and it is ideally suited to bilateral cases. The wounds heal with an excellent cosmetic result.

OrthOracle readers will also find the following associated instructional operative techniques of interest:

Congenital Hip dislocation: Anterior open reduction and Dega acetabuloplasty

Congenital Hip dysplasia: The Birmingham Interlocking Pelvic (Triple) osteotomy

Congenital hip dysplasia: Salters osteotomy

Congenital dislocation of the hip: Proximal femoral varus osteotomy (Blade plate fixation)

 

 

 

Author: Mr Christopher Edward Bache (FRCS Tr & Orth)

Institution: The Birmingham Childrens' Hospital, Birmingham, UK.

Clinicians should seek clarification on whether any implant demonstrated is licensed for use in their own country.

In the USA contact: fda.gov
In the UK contact: gov.uk
In the EU contact: ema.europa.eu